Search Results

BioMidwest

Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development

Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.

September 27, 2023

·

2 min read

BioMidwest

Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development

Evozyne today revealed a breakthrough AI model, developed in collaboration with NVIDIA, that the pharmaceutical industry can use to design therapeutic proteins.

January 12, 2023

·

3 min read

Business

Evozyne Hires Chief Operating Officer to Scale Scientific Operations for Growth

Evozyne named Zach Serber as its chief operating officer, a newly created position charged with directing scientific operations for the fast-growing biology engineering company.

October 18, 2022

·

2 min read

Business

Takeda/Evozyne Partnership Headlines Hot Week for Gene Therapy Deals

Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.

April 6, 2022

·

3 min read

·

Mark Terry

Business

Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies

Evozyne, Inc. announced that it has entered into a strategic research collaboration and license agreement with Takeda to research and develop proteins that could be incorporated into next-generation gene therapies for up to four rare disease targets.

April 5, 2022

·

4 min read

BioMidwest

Evozyne and Takeda Announce Strategic Collaboration and License Agreement

Evozyne, LLC, a privately held molecular engineering technology company founded by life science innovator Paragon Biosciences, announced today the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”).

January 25, 2021

·

4 min read

Business

Evozyne Announces a Strategic Collaboration for Development of Novel Biopharmaceutical Therapeutics

Evozyne, LLC, a privately held molecular engineering technology company founded by life science innovator Paragon Biosciences, announced today the signing of a strategic collaboration with a leading company in rare disorders for the development and commercialization of novel biopharmaceuticals for immune modulation.

February 1, 2021

·

2 min read

BioMidwest

Synthetic Protein Design and Production Publication Confirms Evozyne’s Revolutionary Technology

Publication in peer-reviewed journal Science demonstrates the foundation of the company’s evolution-based, data-driven engineering technology to build artificial functional enzymes

July 23, 2020

·

4 min read

Business

Biospace Movers & Shakers: Maravai, Predictive Oncology, Exagen and More Tap New Execs

With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.

October 20, 2022

·

5 min read

·

Alex Keown

Pictured: Abstract design of computer code/iStock,

Drug Development

Launch of Insilico’s Phase II Program Highlights Generative AI Momentum

Insilico’s AI platform has attracted interest from a growing number of biopharma companies. Meanwhile, several other firms highlight their own AI technologies.

August 11, 2023

·

5 min read

·

Ana Mulero